Francesco Granata is Industrial Partner at FSI. He has a solid and extensive experience in pharmaceutical and biotechnology sectors both in Italy and internationally.
Francesco Granata was Executive Vice President and Member of the Executive Committee of Biogen Idec (NASDAQ: BIIB), one of the leading global biotech companies based in Boston. Previously he was Group Vice President and President of Schering-Plough Europe and Canada. Previously, he held management positions at Pfizer and was CEO of Pharmacia and Dompè Biotec. He began his career in the pharmaceutical world in the Research and Development sector, where he held roles of increasing responsibility both at Italian and international level. In particular, he was medical director for Italy and Southern Europe for Glaxo, responsible for the clinical development of the molecules discovered in the Italian Research Center and Board Member of Glaxo International Research.
Francesco has served as a member of several industry associations: Board Member of Farmindustria (Italy), Head of Italian LAWG, Chairman of Pharma Heads of Europe Committee, Co-Chairman of EFPIA Heads of Europe Committee and Board member of EFPIA.
In Italy Francesco Granata currently sits on the Boards of Neopharmed Gentili, Italfarmaco, Diadem and Greenbone two startups in the medtech sector supported by important venture capital funds. Internationally, he is Chairman of Kiowa Kirin International (international branch of the Japanese Kiowa Hakko Kirin) based in London and Chairman of Sintetica SA. He is Board Member of the Helsinn Group based in Switzerland and Board and Investment Committee member of Helsinn Investment Fund (a venture capital fund with focus on oncology) based in Luxembourg.
He is a medical doctor and he holds a degree from Pavia University.